PI RISK & IMPLICATIONS
Despite standard Ig therapy, patients continue to experience recurrent respiratory infection and chronic lung disease1,2
Risk factors that complicate the approach to PI and impact survival include:
Clinical presentation varies across patient populations and may impact treatment decisions
*Other factors that could lead to infection include inflammatory disease, malabsorption, granulomatous disease, liver diseases, including hepatitis, lymphoma, and other cancers.6
Despite standard Ig therapy, patients with PI experience significant reductions in their quality of life8
Recurrent respiratory infections result in significant activity limitations8
The latest IDF survey of PI patients shows that despite IGRT, nearly 50% of PI patients still experience significant activity limitations annually†
- Patients continue to miss many days from work/school‡
Patients with PI require extensive healthcare utilization8
Based on the latest IDF survey of adults with PI, a significant percentage of PI patients annually require the following:
When selecting an IVIG treatment, individual patient characteristics should be considered
†Patients were asked, “During the past 12 months, how much has he/she been limited in work, play, or normal physical activity as a result of his/her health?” Answers were limited to individuals who currently use Ig replacement.
‡Patients were asked, “Not counting hospitalizations, how many days was the patient too sick to work, go to school, or perform usual activities in the past 12 months?” Answers were limited to individuals who currently use Ig replacement. Those who were retired or too disabled to work were excluded.
IDF=Immune Deficiency Foundation.